Results 21 to 30 of about 88,182,083 (298)

Prescribers’ satisfaction with delivering medications for opioid use disorder [PDF]

Substance Abuse Treatment, Prevention, and Policy, 2021
Abstract Background Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering these two types of MOUD.
Knudsen, Hannah K, Brown, Randy, Jacobson, Nora, Horst, Julie, Kim, Jee-Seon, Kim, Hanna, Madden, Lynn M, Haram, Eric, Molfenter, Todd   +8 more
openaire   +5 more sources

Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021

JAMA Network Open, 2023
This cross-sectional study uses data from the 2021 National Survey on Drug Use and Health to estimate the receipt of medication for opioid use disorder among US adults with past-year opioid use disorder.
Jones, Christopher M., Han, Beth, Baldwin, Grant T., Einstein, Emily B., Compton, Wilson M.   +4 more
openaire   +2 more sources

The Lived Experience of Medication for Opioid Use Disorder

Journal of Addictions Nursing, 2023
Abstract Purpose of the Study Buprenorphine and methadone, when used as maintenance therapy in opioid use disorder (OUD), can significantly reduce the risk of death after an opioid overdose. Despite the many benefits, medication for OUD (MOUD) remains controversial and underutilized.
Aimee Techau, Emily Gamm, Mia Roberts, Lorraine Garcia   +3 more
openaire   +2 more sources

Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems

Addiction Science & Clinical Practice, 2021
Purpose Little is known about prevalence and treatment of OUD among youth engaged in primary care (PC). Medications are the recommended treatment of opioid use disorder (OUD) for adolescents and young adults (youth).
Sarah M. Bagley, Laura Chavez, Jordan M. Braciszewski, Mary Akolsile, Denise M. Boudreau, Gwen Lapham, Cynthia I. Campbell, Gavin Bart, Bobbi Jo H. Yarborough, Jeffrey H. Samet, Andrew J. Saxon, Rebecca C. Rossom, Ingrid A. Binswanger, Mark T. Murphy, Joseph E. Glass, Katharine A. Bradley, PROUD Collaborative   +16 more
doaj   +1 more source

Educating the community about the opioid epidemic and medications for opioid use disorder

The American Journal on Addictions, 2022
AbstractBackground and ObjectivesDespite overwhelming evidence of benefit, medications for opioid use disorder (MOUD) remain stigmatizing and more efforts are needed to educate health care professionals and the general public.MethodsWe developed and evaluated an educational program for graduate students studying health sciences, teaching them to ...
Jill M. Williams, Muzdalifa A. Syed, Aderike Adesanya, George Gardner, Vamsee Chaguturu, Kristen M. Coppola   +5 more
openaire   +2 more sources

Medication for opioid use disorder at hospital discharge is not associated with intravenous antibiotic completion in post-acute care facilities

Therapeutic Advances in Infectious Disease, 2022
Background: People with opioid use disorder and severe infections may complete their prolonged courses of outpatient parenteral antimicrobial therapy at a post-acute care facility due to adherence and safety concerns.
Edward C. Traver, Patrick R. Ching, Shivakumar Narayanan   +2 more
doaj   +1 more source

Medicaid expansion and treatment for opioid use disorders in Oregon: an interrupted time-series analysis

Addiction Science & Clinical Practice, 2019
Background The study examined the association of the Affordable Care Act’s 2014 Medicaid expansion on the use of psychosocial services and pharmacotherapies for opioid use disorders among Oregon Medicaid recipients.
Dennis McCarty, Yifan Gu, John W. McIlveen, Bonnie K. Lind   +3 more
doaj   +1 more source

Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program

Substance Abuse Treatment, Prevention, and Policy, 2023
Background Medication for opioid use disorder (MOUD) is the gold standard treatment for opioid use disorder. Traditionally, “success” in MOUD treatment is measured in terms of program retention, adherence to MOUD, and abstinence from opioid and other ...
Megan K. Reed, Kelsey R. Smith, Francesca Ciocco, Richard W. Hass, Avery Lin Cox, Erin L. Kelly, Lara C. Weinstein   +6 more
doaj   +1 more source

The impact of stigma on people with opioid use disorder, opioid treatment, and policy.

, 2022
Illicit drug use disorders are the most stigmatised health conditions worldwide, and stigma acts as a meaningful barrier to treatment entry and treatment provision.
Lubman, Dan I, Barnett, Anthony, Nielsen, Suzanne, Cheetham, Ali, Picco, Louisa   +4 more
core   +1 more source

Impact of Medication Assisted Treatment on Opioid Use Disorder. [PDF]

, 2022
Opioid use disorder has been an increasing problem in the United States. Opioid analgesics are now responsible for more deaths than the number of deaths from both suicide and motor vehicle crashes.
Portillo, Carlos
core   +2 more sources